KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $7.6 billion.

  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity rose 1114.66% to $7.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 billion, marking a year-over-year increase of 569.82%. This contributed to the annual value of $7.0 billion for FY2024, which is 215.35% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Liabilities and Shareholders Equity stood at $7.6 billion for Q3 2025, which was up 1114.66% from $7.5 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Liabilities and Shareholders Equity registered a high of $7.6 billion during Q3 2025, and its lowest value of $5.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $6.6 billion (2023), whereas its average is $6.6 billion.
  • The largest annual percentage gain for Biomarin Pharmaceutical's Liabilities and Shareholders Equity in the last 5 years was 2291.44% (2021), contrasted with its biggest fall of 293.3% (2021).
  • Biomarin Pharmaceutical's Liabilities and Shareholders Equity (Quarter) stood at $6.0 billion in 2021, then rose by 6.17% to $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then increased by 2.15% to $7.0 billion in 2024, then rose by 8.96% to $7.6 billion in 2025.
  • Its last three reported values are $7.6 billion in Q3 2025, $7.5 billion for Q2 2025, and $7.1 billion during Q1 2025.